ArticleOPEN ACCESS

Vorinostat is victorious in GVHD prevention

Blood
DOI: 10.1182/blood-2017-08-802249
5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).1

Cite

CITATION STYLE

APA

Holtan, S. G., & Weisdorf, D. J. (2017, October 12). Vorinostat is victorious in GVHD prevention. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-08-802249

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free